🔥 Get NASDAQ: KTTA on your Screen Now!

NASDAQ: KTTA Greetings Investors, Every year, 13 million to 14 million Americans have major depression Of those who seek treatment, 30% to 40% will not get better or fully recover with standard antidepressants. Sadly, this puts them at greater risk of alcohol and drug abuse, hospitalization, and suicide attempts. Depression has been alarmingly on the rise in the past year with what the world has gone through. The pandemic has tripled the rate of depression in US adults in all demographic groups— especially in those with financial worries—and the rise is much higher than after previous major traumatic events, according to a study published in JAMA Network Open. Now, though, a growing body of research shows there may be new hope: the anesthetic drug ketamine. As stated in the Psyciatric Times, “Ketamine has caused quite a stir in psychiatric practice. Sub-anesthetic administrations of ketamine have been shown to markedly improve symptoms of depression and anxiety!” Ketamine was only introduced into clinical practice in the 1960’s but STILL continues to be both clinically useful and scientifically fascinating today. Recreational ketamine use however, is not legal, and is associated with dangers and a serious risk of developing dependence and addiction. Even though it may get a bad reputation for that reason, ketamine is being recognized as effective in treating some mental illnesses and even substance abuse addictions under medical supervision. Furthermore, the doses used for medical purpose are much lower than the doses used recreationally, and studies have shown that the risk of developing addiction at this dose is absent. With a lot of research done already, and more in progress, the world is quickly learning that ketamine can be beneficial in healthcare. It was a huge milestone that a psychedelics ETF hit the NYSE this year! The AdvisorShares Psychedelics ETF provides exposure to biotechnology, pharmaceutical and life sciences companies that the firm deems are “leading the way in this nascent industry.” All of this may soon shine a spotlight on Pasithea Therapeutics Corp. (NASDAQ: KTTA) who is quietly emerging as a major player in the biotech industry! [READ FULL REPORT ON NASDAQ:KTTA]( Copyright 2022 © PTE.la is owned and operated by CareBear Marketing Group LLC. [Disclaimer and Privacy]( more Information please contact Support@pte.la Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. You received this message as part of your subscription to PTE. PTE is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “PTE” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and the number of shares here. We do not own any shares in KTTA. We have been compensated Five-Thousand Dollars Cash ($5,000) via bank wire transfer from a third party Tradigital Marketing Group (read Tradigital Marketing Group Disclaimer here: ) for a 1 Day Marketing Program regarding KTTA with a start date of 5/23/2022 to 5/24/2022. PTE’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, PTE often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](